167 related articles for article (PubMed ID: 38552037)
1. Is fibroblast growth factor 11 (FGF11) a predictive marker for breast cancer?
Aktürk Esen S; Karabulut S; Buyukaksoy M; Kurt Cevik G; Ceylan F; Civelek B; Şendur MAN; Erdogan F; Uncu D
Medicine (Baltimore); 2024 Mar; 103(13):e37656. PubMed ID: 38552037
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma.
Ye SB; Zhang H; Cai TT; Liu YN; Ni JJ; He J; Peng JY; Chen QY; Mo HY; Jun-Cui ; Zhang XS; Zeng YX; Li J
J Pathol; 2016 Nov; 240(3):329-340. PubMed ID: 27538493
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway.
Wu X; Li M; Li Y; Deng Y; Ke S; Li F; Wang Y; Zhou S
J Transl Med; 2021 Aug; 19(1):353. PubMed ID: 34404435
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 11 Enables Tumor Cell Immune Escape by Promoting T Cell Exhaustion and Predicts Poor Prognosis in Patients with Lung Adenocarcinoma.
Zhai B; Wu J; Li T
J Oncol; 2023; 2023():9303632. PubMed ID: 37250453
[TBL] [Abstract][Full Text] [Related]
5. FGF11 influences 3T3-L1 preadipocyte differentiation by modulating the expression of PPARγ regulators.
Lee KW; Jeong JY; An YJ; Lee JH; Yim HS
FEBS Open Bio; 2019 Apr; 9(4):769-780. PubMed ID: 30984550
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation.
Yang J; Kim WJ; Jun HO; Lee EJ; Lee KW; Jeong JY; Lee SW
Oncol Rep; 2015 Nov; 34(5):2745-51. PubMed ID: 26323829
[TBL] [Abstract][Full Text] [Related]
9. Silencing of hypothalamic FGF11 prevents diet-induced obesity.
Cho JH; Kim K; Cho HC; Lee J; Kim EK
Mol Brain; 2022 Sep; 15(1):75. PubMed ID: 36064426
[TBL] [Abstract][Full Text] [Related]
10. FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability.
Lee KW; Yim HS; Shin J; Lee C; Lee JH; Jeong JY
FEBS Lett; 2017 Jan; 591(2):348-357. PubMed ID: 28027390
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Induced Fibroblast Growth Factor 11 Stimulates Osteoclast-Mediated Resorption of Bone.
Knowles HJ
Calcif Tissue Int; 2017 Apr; 100(4):382-391. PubMed ID: 28097375
[TBL] [Abstract][Full Text] [Related]
13. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu W; Jiang Y; Xu L; Li C; Wang J; Liu Z; Xue D; Gu Y; Zhong Z; He S; Wang S; Zhou W; Pan H
Jpn J Clin Oncol; 2023 Jun; 53(6):463-471. PubMed ID: 36757139
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1α/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma.
Yin M; Lu C; Zhou H; Liu Q; Yang J
Cancer Manag Res; 2023; 15():753-763. PubMed ID: 37525667
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic Analysis Reveals Fibroblast Growth Factor 11 (FGF11) Role in Brown Adipocytes in Thermogenic Regulation of Goats.
Jiang T; Su D; Liu X; Wang Y; Wang L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446019
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.
Ferroni P; Riondino S; Laudisi A; Portarena I; Formica V; Alessandroni J; D'Alessandro R; Orlandi A; Costarelli L; Cavaliere F; Guadagni F; Roselli M
Oncologist; 2016 Sep; 21(9):1041-9. PubMed ID: 27388232
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 11 Inhibits Hepatitis B Virus Gene Expression Through FXRα Suppression.
Seong MS; Jang JA; Jeong YR; Kim YB; Kyaw YY; Kong HJ; Lee JH; Cheong J
J Microbiol; 2023 Jul; 61(7):693-702. PubMed ID: 37646922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
